Does OSIMERTINIB Cause Malignant neoplasm progression? 2,920 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 2,920 reports of Malignant neoplasm progression have been filed in association with OSIMERTINIB (TAGRISSO). This represents 10.5% of all adverse event reports for OSIMERTINIB.
2,920
Reports of Malignant neoplasm progression with OSIMERTINIB
10.5%
of all OSIMERTINIB reports
574
Deaths
354
Hospitalizations
How Dangerous Is Malignant neoplasm progression From OSIMERTINIB?
Of the 2,920 reports, 574 (19.7%) resulted in death, 354 (12.1%) required hospitalization, and 74 (2.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 2,920 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
Disease progression (607)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which OSIMERTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN